Additionally, CXCR4/CXCL12 signalling enhances CSC populations to mediate resistance by retaining a portion of quiescent, drug-tolerant cells, which are capable of repopulating the tumour after treatment is paused [18]. The gene discussed is CXCR4; the disease is neoplasm.